Navigation Links
S*BIO's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models

SINGAPORE, Feb. 28, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that its novel dual mTOR/PI3 Kinase inhibitor SB2343 demonstrated excellent pharmacokinetic/pharmacodynamic (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive and resistant xenograft models. In vivo and in vitro data on SB2343 were presented at American Association of Cancer Research (AACR) Special Conference on Targeting PI3K/mTOR Signaling in Cancer held in San Francisco.

SB2343 is a uniquely selective and orally active mTOR/PI3 Kinase inhibitor that targets the PI3K signalling pathway with high and equivalent potency against both mTOR and PI3K enzymes.  The combined modulation of these two kinases with SB2343 provides an attractive and powerful therapeutic approach for the treatment of patients with a wide range of cancers alone or in combination.

"The pre-clinical data for our mTOR/PI3K inhibitor SB2343 strongly demonstrate its unique treatment potential in a broad range of cancers that are dependent on elevated PI3K signalling," said Jan-Anders Karlsson, CEO of S*BIO. "The advancement of our diversified pipeline shows our continued commitment to develop high quality products in the oncology area."

Abstracts:Poster Session A (Friday, February 25th)SB2343, a novel tetra-substituted purine, inhibits mTOR and PI3K equipotently, has favorable pharmacokinetic and pharmacodynamic properties and is orally efficacious in various cancer models

SB2343 is a potent dual mTOR/PI3K inhibitor with excellent pharmaceutical and pharmacodynamic properties, tolerability and anti-tumor efficacy.  SB2343 has therapeutic potential for the treatment of a broad range of Rapamycin-sensitive, but also – resistant cancers. Efficacious doses of SB2343 were selected after pharmacokinetic and biomarker analysis of PC3 tumor-bearing mice, treated with single oral doses.  Anti-tumor efficacy of SB2343 was evaluated in mouse xenograft models following once per day oral dosing.

Poster Session B (Saturday, February 26th)A novel series of tetra-substituted purines potently inhibit mTOR and PI3K, exhibit striking selectivity and demonstrate good pathway inhibition in vivo

Following structure activity relationship (SAR) investigations, SB2343 was selected for testing in vivo. A single dose of 25 mg/kg of SB2343 resulted in efficient and sustained inhibition of phosphorylation of Akt and S6 in tumor tissues. Lead optimization has resulted in the selection of SB2343 as a potent and selective orally bioavailable mTOR and pan-PI3 kinase inhibitor.

About S*BIO Pte LtdS*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's HDAC inhibitor, SB939, is currently in Phase 2 trials. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and is now completing Phase 2 trials.  It has received orphan drug designation from the U.S. and the E.U. regulatory authorities. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578 in North America and Europe. S*BIO's SB1317, a novel multikinase inhibitor, is in Phase 1 trials and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital a subsidiary of EDBI (EDB Investments), Aravis Ventures, Mitsui Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. More information about S*BIO can be found at*BIO Pte Ltd:Russo PartnersStephen Keith Rhind, Ph.D.Tony Russo +1 212-845-4251Senior Vice President, Corporate DevelopmentTony.Russo@russopartnersllc.comTel: +65 6827 5000 (Singapore) Andreas Marathovouniotis +1

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin
2. Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions
3. ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
4. Tolerx Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody
5. Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration
6. Novel Night Time Healing is Key to Shoulder Pain Relief From ROTATORELIEVER
7. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
8. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
9. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
10. IDRI Awarded Grant from Bill and Melinda Gates Foundation to Identify Candidates for Novel TB Drugs
11. Omeros Licenses Novel Antifibrinolytic Agents
Post Your Comments:
(Date:10/13/2015)... -- Synapse Biomedical Inc. ( ) reported today that ... use of the NeuRx ® Diaphragm Pacing System ... the United States and patient ... PAS study group met their initial enrollment goal ahead ... expanded the enrollment target to 150 participants.   ...
(Date:10/13/2015)... DUBLIN , Oct. 13 2015 ... addition of the "US & European markets ... report to their offering. --> ... "US & European markets for Meniscal Repair - ... --> Research and Markets ( ...
(Date:10/13/2015)... , Oct. 9, 2015 Research and Markets ... "Kombucha Market by Types (Bacteria, Yeast, Mold, Others), ... Mangoes, Flowers, Others), & by Region - Forecasts to ... --> --> The ... last few years. In terms of value, the market ...
Breaking Medicine Technology:
(Date:10/13/2015)... , ... October 13, 2015 , ... The documentary ... Laemmle Music Hall in Beverly Hills October 2 - 8, coinciding with National Hereditary ... Award® consideration, the film takes us through the lives of women - and men ...
(Date:10/13/2015)... ... 13, 2015 , ... The added calories and sugar in an average trick-or-treat ... a parent to do? Registered dietitians from Retrofit , the leading corporate weight ... year. , “Halloween is a high-calorie holiday,” said Dara Aronow, Registered Dietitian, Retrofit. ...
(Date:10/13/2015)... WEST LAFAYETTE, Ind. (PRWEB) , ... October 13, ... ... to establish a new Pillars of Excellence in the Life Sciences Initiative aimed ... part of Purdue’s recently announced $2 billion “Ever True” capital campaign. , The ...
(Date:10/13/2015)... ... October 13, 2015 , ... Vision Group Holdings, the largest LASIK provider in ... brands including The LASIK Vision Institute and TLC Laser Eye Centers, Vision Group Holdings ... laser vision correction. , Global Laser Vision will continue to operate in San Diego ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... enterprise focused on cancer patients, today announced a new partnership with the ... battling this rare type of non-Hodgkin’s lymphoma, their families and physicians. , ...
Breaking Medicine News(10 mins):